1374507-25-1

Basic information

• Product Name: CO-1686 intermediate 1
• Synonyms: CO-1686 intermediate 1;N-(3-((2-chloro-5-(trifluoromethyl)pyri midin-4-yl)amino)phenyl)acrylamide;N-[3-[[2-Chloro-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide;N-(3-{[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]amino}phenyl)prop-2-enamide
• CAS NO: 1374507-25-1
• Molecular Formula: C₁₄H₁₀ClF₃N₄O
• Molecular Weight: 342.7036096
• Mol File: 1374507-25-1.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 519.7±50.0 °C(Predicted)
• Appearance: /
• Density: 1.476±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 13.21±0.70(Predicted)
• CAS DataBase Reference: CO-1686 intermediate 1(CAS DataBase Reference)
• NIST Chemistry Reference: CO-1686 intermediate 1(1374507-25-1)
• EPA Substance Registry System: CO-1686 intermediate 1(1374507-25-1)

Safety Data

• Hazardous Substances Data: 1374507-25-1(Hazardous Substances Data)

Usage

Description

CO-1686 intermediate 1 is a chemical compound that serves as an intermediate in the synthesis of various pharmaceuticals and other chemical products. It is characterized by its unique molecular structure and functional groups, which contribute to its diverse applications across different industries.

Uses

Used in Pharmaceutical Industry:
CO-1686 intermediate 1 is used as a key intermediate for the synthesis of potent BTK and JAK3 dual inhibitors. These inhibitors play a crucial role in the development of novel therapeutics for various diseases, including autoimmune disorders and cancer.
Used in Chemical Industry:
CO-1686 intermediate 1 is utilized as a building block in the production of various chemical products, such as dyes, pigments, and other specialty chemicals. Its unique chemical properties make it a valuable component in the synthesis of these materials.
Used in Research and Development:
CO-1686 intermediate 1 is employed as a research tool in the study of various biological and chemical processes. Its unique structure and reactivity allow scientists to explore new reaction pathways and develop innovative strategies for drug discovery and chemical synthesis.

Upstream product

• 92146-82-2 tert-butyl 3-aminobenzoate 
• 17090-15-2 Ν-(3-nitrophenyl)acrylamide 
• 99-09-2 3-nitro-aniline 
• 3932-97-6 2,4-dichloro-5-trifluoromethylpyrimidine 
• 16230-24-3 Ν-(3-aminophenyl)prop-2-enamide 
• 68621-88-5 (3-aminophenyl)carbamic acid tert-butyl ester 
• 1374507-23-9 tert-butyl (3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)aminocarboxylate 
• 814-68-6 acryloyl chloride 
• 146651-75-4 tert–butyl (2–aminophenyl)carbamate 
• 1374507-24-0 N′-(2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)phenyl-1,3-diamine 

Relevant articles and documents

Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors

Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) are very promising targets for hematological malignancies and autoimmune diseases. In recent years, a few compounds have been approved as a marketed medicine, and several are undergoing clinical trials. By recombining the dominant backbone of known active compounds, constructing a foused library, and screening a broad panel of kinases, we found a class of compounds with dual activities of anti-BTK and anti-JAK3. Some of the compounds have shown 10-folds more active in the enzyme and cell-based assays than a known active compound. Furthermore, liver microsome stability experiments show that these compounds have better stability than ibrutinib. These explorations offered new clues to discover benzoxaborole fragment and pyrimidine scaffold as more effective BTK and JAK3 dual inhibitors.

A including a spiro ring or bridge of the pyrimidines

The invention discloses a spiral ring or bridged ring containing pyrimidine compound. The compound has a structure shown as formula I, and also can be an enantiomer, a diastereomer, a pharmaceutically acceptable salt, a prodrug molecule, a solvate, a taut

2,4-dibasic miazines compound

The invention belongs to the field of medical chemistry, relates to a 2,4-dibasic miazines compound and specifically relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof, a drug compound thereof and an application thereof in treating EGFR or/and ALK mediated diseases.